Skytrofa is a human growth hormone used to treat growth failure due to inadequate secretion of endogenous growth hormone (gh) in children 1 year and older who weigh at least 11.5 kg (25.3 lb) Skytrofa is also used to replace endogenous growth hormone in adults with growth hormone deficiency (ghd) It is given as a subcutaneous injection once a week. 3 mg, 3.6 mg, 4.3 mg, 5.2 mg, 6.3 mg, 7.6 mg, 9.1 mg, 11 mg and 13.3 mg. Overview lonapegsomatropin ascendis pharma is a medicine that is used to improve growth in children and adolescents who do not produce enough growth hormone (growth hormone deficiency or ghd) The medicine is intended for children and adolescents from 3 up to 18 years of age
Ghd is rare, and lonapegsomatropin ascendis pharma was designated an ‘orphan medicine’ (a medicine used in rare. Consider how a weekly administration could align with daily routines and treatment schedules Review key features, how it works, and what to consider when discussing treatment options Skytrofa is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (gh) (1). It's given as a weekly injection under the skin using an autoinjector, which can be done at home Common side effects include viral infection, fever, cough, nausea, and vomiting.
WATCH
